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A novel, tissue occlusive poly(ethylene glycol) hydrogel material
Abstract
The use of guided bone regeneration (GBR) techniques requires new materials meeting the needs of
clinical application. Design criteria for GBR devices are biocompatibility, tissue occlusion, space
provision, and clinical manageability. This study evaluates a novel biodegradable poly (ethylene glycol)
(PEG) based material as tissue occlusive membrane. A subcutaneous implant model in rats was
developed to test the barrier function of the PEG hydrogels over time. Fourteen rats received three
membrane implants and two positive controls each. Explants were collected over a period of 7 months.
Histological analysis revealed that for at least 4 months cellular infiltration in the membrane explants
was lower than 1% of that of the positive controls. Therefore, the PEG based hydrogel can be regarded
as tissue occlusive during this period of time. A barrier function seems to be maintained for up to 6
months. In vitro degradation studies performed with the same PEG constructs confirm the in vivo result.
In conclusion, our results indicate that this novel PEG-based material has potential for use as a GBR
barrier membrane.
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Abstract 
The use of guided bone regeneration (GBR) techniques requires new materials 
meeting the needs of clinical application. Design criteria for GBR devices are 
biocompatibility, tissue occlusion, space provision and clinical manageability. This 
study evaluates a novel biodegradable poly(ethylene glycol) (PEG) based material as 
tissue occlusive membrane. A subcutaneous implant model in rats was developed to 
prove the barrier function of the PEG hydrogels over time. Each animal (n = 14, adult 
female rats) received 3 membrane implants and 2 positive controls. Explants were 
collected over a period of 7 months. Histological analysis revealed that for at least 4 
months cellular infiltration in the membrane explants was lower than 1% of that of the 
positive controls. Therefore, the PEG based hydrogel can be regarded as tissue 
occlusive during this period of time. A barrier function seems to be maintained for up 
to 6 months. In vitro degradation studies performed with the same PEG constructs 
confirm the in vivo result. However, the membrane degradation is faster in vitro due 
to increased swelling compared to the in vivo situation. These results demonstrate that 
this novel PEG-based material has potential for use as GBR barrier membrane.  
 
Keywords: Hydrogel; Bone regeneration; Dental implant; Animal model 
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1. Introduction 
In clinical practice, tissue regeneration often needs to be guided to result in a new and 
functional physiology. In dental implantology, for example, cell or tissue occlusive 
membranes help to restore functional osseous tissue by allocating space for bone 
growth and preventing competition between bone regeneration and soft tissue in-
growth1. This technique, called guided bone regeneration (GBR), was introduced 
almost two decades ago2 and proved useful in the generation of an adequate bone 
volume needed for total coverage of oral implants3. In the last decade it became the 
standard procedure for the treatment of bone defects around osseointegrated dental 
implants and for ridge augmentation prior to implant placement3. Materials used for 
GBR membranes have to meet criteria such as biocompatibility, cell or tissue 
occlusion, space provision and tissue integration4. Membranes made of several 
different materials are available on the market, non-resorbable (e.g. expanded PTFE) 
or resorbable (e.g. poly(lactic acid) or collagen)3. The advantage of resorbable 
materials is that they do not require a second surgery for membrane removal. The vast 
majority of membranes available on the market today have to be trimmed to the 
desired shape. Especially for complicated shapes (e.g. when used around a dental 
implant) or sites that are difficult to reach, a liquid applicable, in situ forming 
biodegradable membrane would offer many advantages. 
 
Poly(ethylene glycol) (PEG) hydrogels are known for their biocompatibility5 and are 
already used in several medical devices available on the market, e.g. as adhesion 
barrier for use in abdominopelvic procedures6, as seal to augment sutured dura 
closures following cranial surgical procedures7, or as sealant for leaks around sutures 
in natural or artificial blood vessels8. Lately, significant research efforts have been 
  3 
directed towards the use of biodegradable PEG hydrogels for the controlled release of 
biologically active factors9-12. Most of these gels have in common that they degrade 
by hydrolysis of ester groups between the PEGs in the course of a few days to a few 
weeks in vivo. For GBR applications, a controlled duration of the barrier function for 
several months is desirable3.  
 
The present study was carried out to test the tissue occlusiveness of a PEG-based, in 
situ applicable hydrogel membrane, the hydrolysis rate of which has been optimized 
for GBR applications by tuning the crosslink density of the system. Since gel 
formation is accomplished by end linking of two multifunctional PEG molecules 
through a Michael type addition reaction in aqueous buffer9, a solid hydrogel is 
obtained in situ under physiological conditions within seconds to minutes after mixing 
without harming the surrounding tissue. The flow of the material before it has gelled 
is controlled by a viscosity modifier added to the buffer solution to allow an easy 
application of the material directly on the site of surgery. After gelation the material 
prevents tissue in-growth and direct connection of tissues separated by it, until the 
PEG-hydrogel reaches a certain level of degradation by hydrolysis. The degradation 
products consisting of water-soluble PEG undergo renal clearance5. 
 
A subcutaneous implant model in the rat was chosen to evaluate the tissue 
occlusiveness of the PEG-hydrogel. As fibrin is known to be an excellent substrate for 
fibroblasts, polyvinyl alcohol (PVA) sponges were soaked with fibrin and embedded 
in a PEG-hydrogel to yield a three-dimensional barrier around the fibrin matrix13. 
Degradation of the PEG-hydrogel was tested in vitro and in a subcutaneous in vivo 
model in rats. The histology of implanted samples revealed that cell in-growth into the 
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material is reduced to 0.2% of the control values and tissue in-growth to start not 
earlier than 4 months after implantation. Therefore, this easy applicable PEG-based 
hydrogel could be used as adhesion barrier in abdominal surgery and as guided bone 
regeneration membrane in dental implantology.  
 
2. Materials and Methods 
2.1 PVA/fibrin sponges 
Dry, highly porous polyvinyl alcohol (PVA) sponges were purchased from M-PACT, 
(1040 OCL Pkwy, Eudora, KS 66025 USA; PVA Disk, 12.7 mm × 3 mm, REF# 
Q608303, swollen in deionized water, frozen in liquid nitrogen, and then cut into 
cylinders of 3 mm diameter and 3 mm in height. The cut sponges were sterilized by 
autoclaving in deionized water. Subsequently, they were dried by lyophilisation and 
stored under sterile conditions until needed. 
For coating the dry and sterile sponges with fibrin the TISSUECOL Kit from Baxter 
was used. The kit components (human fibrinogen and human thrombin) were 
dissolved with the provided solutions according the recommendations of the 
manufacturer. The final fibrinogen working concentration of 1.75 – 2.75% was 
achieved by diluting with sterile PBS. The dry sponges were pre-wetted with 8 μl of 
fibrinogen solution. For every sponge 10 μl of fibrinogen solution were mixed with 
10 μl of thrombin solution in an Eppendorf tube and pipetted onto the sponges. The 
solutions were quantitatively absorbed by the sponges. In order to ensure complete 
coagulation the sponges were placed into an incubator at 37°C for at least half an 
hour. The sponges were stored in sterile petri dishes until entrapment in the membrane 
material or implantation. 
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 2.2 Implant preparation 
Implants were prepared at room temperature under sterile conditions in cylindrical 
stainless steel molds (Ø 7 mm, height 7 mm).  
Hydrogels were formed by end linking 4-arm PEG-thiol, Mn = 2.3 kDa, and 8-arm 
PEG-acrylate, Mn = 2.3 kDa, (both from Nektar Therapeutics, Huntsville AL) through 
a Michael type addition reaction between the acrylate and thiol endgroups, in slightly 
basic aqueous buffer9. The acrylate component was dissolved in 52 mM 
triethanolamine (Merck, PhEur) in endotoxin-free water, adjusted to pH 7.6 with 
hydrochloric acid (Merck, PhEur) and containing 2.3 wt% of carboxymethyl cellulose 
(Cekol 30 000, Noviant, Nijmegen, Netherlands, PhEur) in order to control the flow 
of the material before gelation had completed. For the thiol component 2.3 wt% of 
carboxymethyl cellulose (CMC) in endotoxin-free water was used. The total PEG 
content of the system was ca. 29 wt% (corresponding to the equilibrium concentration 
in PBS at 37°C) and the total triethanolamine/HCl concentration was ca. 20 mM. The 
amounts of each buffer were adjusted to yield equal volumes of the two PEG 
solutions. The mixture of all four components had pH 7.4. 
Equimolar amounts (with respect to their endgroups) of the sterile filtered PEGs were 
packed in glass syringes. The two buffer solutions were packed in plastic syringes 
with female Luer lock and autoclaved.  
Each PEG component was dissolved in its buffer by syringe-to-syringe mixing, after 
which the syringes with the PEG solutions were attached to a static mixer. Upon 
expelling the contents of the syringes, the gelation process started. Immediately after 
each mold had been filled, a PVA/fibrin sponge was placed in the gelling mixture. 
Special care was taken to make sure that the sponges were well centered and 
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surrounded on each side by 2 mm of hydrogel (Fig. 1b). Then, the mold was covered 
and the hydrogels were allowed to cure at room temperature for ca. 1 hour, after 
which they were transferred to sterile 10 mM PBS (pH 7.4) and stored in an incubator 
at 37°C overnight. Constructs, consisting of the PVA/fibrin core and a PEG shell, that 
were not implanted were used for the in vitro degradation study, which was performed 
twice in order to test reproducibility. The constructs were incubated in 10 ml of 
30 mM PBS (pH 7.4) at 37°C. At regular intervals the constructs were taken from the 
buffer solution, blotted dry, and weighed. The pH of the buffer solution was 
determined and, if the value had dropped below 7.3, the buffer was replaced by fresh 
30 mM PBS (pH 7.4). The disintegration of the gel constructs is given as relative 
weight based on the weight of the freshly cast gel.  
 
2.3 Rheological analysis 
Rheology was performed on a Physica MCR 300 rheometer, equipped with a parallel 
plate geometry with a diameter of 25 mm and a Physica PTD 150 Peltier element, 
keeping the temperature at 37.0±0.1°C. Storage (G’) and loss (G”) moduli as well as 
phase angle (δ) were measured during the gelation process at amplitude γ = 2% and 
frequency ω = 10 s-1. Immediately after ca. 0.5 ml of material was applied (t = 0) 
through a static mixer (in case of the formulation with CMC) or using a pipette (in 
case of the formulation without CMC), the plate was lowered to a gap of 1.0 mm, any 
superfluous material was trimmed away, and the measurement was started. 
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2.4 Implantation 
In a surgical procedure, fourteen adult female Sprague Dawley rats (200 – 300 g in 
weight) were anesthetized by gas inhalation (Isoflurane, Halocarbon Laboratories) 
and each received four implants randomly distributed over four dorsal subcutaneous 
pockets (Fig. 1a). In three of the pockets a construct consisting of the PVA/fibrin core 
surrounded by a PEG shell was placed and in the fourth pocket two PVA/fibrin 
sponges were placed as positive control. The incisions were closed with staples. The 
animal test protocol was approved and controlled by the ethical committee of the local 
authorities.  
 
2.5 Sample preparation 
Animals were sacrificed using CO2 gas, and the samples explanted and weighed. 
Subsequently, they were fixed (4% PFA/PBS, overnight) and dehydrated (series of 
70%, 90% and 100% ethanol for 24 hours, each with one exchange of buffer at room 
temperature). The dehydrated samples were infiltrated for 36 hours in Histocryl 
solution (London Resin Company Ltd), which was exchanged twice during 
infiltration, and were then embedded in gelatin capsules (Electron Microscopy 
Science, size 13) with freshly catalyzed Histocryl solution. Serial sections of 4 μm 
over a distance of 50 – 100 μm were prepared on a Rotary Microtome (MICROM) 
with a d-shaped knife. The sections were stained with Meyer’s haematoxylin (Merck) 
and an aqueous Eosin solution (1%, Sigma Aldrich), mounted in Mowiol 4-88 
(Calbiochem) and analyzed microscopically for the in-growth of fibroblasts into the 
PVA/fibrin core. For quantitative analysis the histological sections were stained with 
DAPI (Molecular Probes). 
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2.6 Cell invasion analysis 
The degree of cell invasion into PVA/fibrin cores was quantified by counting DAPI 
stained cell nuclei in 4 µm thick histological sections of tissue explants by automated 
image analysis, using Object-Image v2. Each explant was analyzed at three levels. 
Four to five images (0.66 × 0.45 mm2) from each of three adjacent tissue slices of the 
three levels formed an image stack of 36 to 45 images and were binarized with a 
common threshold, given by an optimal separation of nuclei. Due to staining and 
image acquisition differences, mean nuclei area varied slightly between different 
images of the same explant. Therefore, for each image a mean nuclei area was 
determined from all freestanding nuclei. The total number of cell nuclei was then 
calculated from the total black area divided by the mean nuclei area. Using this 
method connected nuclei and nuclei cluster were accounted for correctly. 
 
 
3. Results and Discussion 
3.1 Hydrogel formation 
Mixing each of the PEGs with its buffer solution yielded two viscous, slowly flowing 
solutions, which could be mixed with help of a static mixer. At 37°C this mixture 
yielded a firm hydrogel in ca. 35 s, in the course of which no significant flow could be 
observed. Formation of the hydrogel was monitored with dynamic rheology (Fig. 2). 
Before gelation, the solution showed ideal viscous behavior with a loss angle δ = 90°. 
Ca. 30 s after mixing, the mixture rapidly gelled and the storage modulus G’ increased 
by 9 decades in the course of ca. 1 min, with the gel approaching ideal elastic 
behavior (δ ≈ 1°). A formulation without CMC (open circles in Fig. 2) showed almost 
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identical behavior, with exception of the loss modulus G” which decreased at the 
point of gelation. 
  
3.2 Subcutaneous implant model 
The present study was performed to test a PEG-based hydrogel for degradation 
properties in vitro, in vivo, and for tissue occlusiveness in vivo. Following 
implantation (Fig. 1a) the animals remained in good health and tolerated the materials 
well. At harvest of the implants the histology of the samples supported the initial 
finding, since the capsules, which formed around the constructs consisted mainly of 
fibroblasts and adipocytes. Inflammatory cells like macrophages and neutrophiles 
were not observed. At 3 months the implants were still intact and surrounded by a thin 
cell-containing capsule visible after H&E staining as a thin blue layer around the 
implant (Fig. 4a). Cellular infiltration of the PEG shell or the PVA/fibrin sponge was 
hardly detectable at 3 months (Fig. 4a). Six months post-implantation the implants 
started to disintegrate and cells, forming clusters, could be detected in the PVA/fibrin 
sponge and the PEG shell. The counting of cell nuclei in the PVA/fibrin sponge 
revealed that in absence of the PEG shell the average cell density (±SD) determined 
from control implants of all time points was 1.3±0.3 106 cells per mm3 (n=12). Thus, 
cellular infiltration was almost completed after 1 month (Fig. 7). In contrast, the cell 
density in the PEG shielded test sponges was significantly lower (one-way ANOVA 
test with Bonferroni adjustment, P < 0.001) than in the control unshielded PVA/fibrin 
sponges (Fig. 8).  
Between 1 and 4.3 months the number of cells located in the PVA/fibrin sponge 
covered by a PEG gel increased slightly from 0.02±0.04% to 0.11±0.23% of the 
control implants. A clear increase in cell infiltration was observed after 6 months, 
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although the actual number of cells in the sponges covered by a PEG shell was still 
below 1% of that in the PVA/fibrin control sponges. After 7 months, the PEG 
membranes were mostly disintegrated and the number of cells had increased to 
2.8±4.7% of that in the positive control. The strong variation between individual 
samples at this time point may be explained by slight variations in the time to full 
degradation between the individual constructs. The maximal cell density determined 
at 7 months was 14% of the control site showing that with the loss of the barrier 
function a massive cell infiltration occurred. Since cells could be detected in all 
constructs at all time points total cell occlusion of this material in this model persists, 
if at all, in vivo only at time points earlier than 1 month. Histology revealed that cell 
clusters or primitive tissues could only be detected in the PVA/fibrin core covered by 
PEG hydrogel after 6 months. Therefore, single cells can invade the PEG-material in 
this in vivo setting in the first month. It cannot be excluded that formation of 
microcracks in the PEG shell, caused by normal activity of the animals in enriched 
cages could facilitate the invasion of single cells. Nevertheless, the material remains 
tissue occlusive for more than 4 months. For guided tissue regeneration, involving not 
only the alveolar bone but also cementum and periodontal ligaments, it was shown 
that space provision by the membrane is more important than cell occlusiveness14. 
The same applies for guided bone regeneration where an increase in pore size 
between 8 and 100 µm, permitting cell in-growth, even improved bone repair in a 
bone augmentation model in the rat15. This suggests that the invasion of single cells 
induces no adverse effects on bone regeneration. In case the pore size exceeds 300 µm 
in diameter, bone regeneration compared to membranes without pores is reduced, 
even if space provision capabilities of both membranes is identical16. As pores up to 
100 µm improve and 300 µm pores compromise bone regeneration, tissue occlusion 
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and not cell occlusion decides upon the outcome of the guided bone regeneration 
approach. Therefore, the tissue occlusive PEG-based hydrogel is suitable for the 
guided bone regeneration approach, especially due to its ease of use. 
 
3.3 Comparison of in vivo and in vitro degradation  
Parallel to the in vivo study, constructs were degraded in vitro and monitored by 
weighing. The weight of each explant or each in vitro degrading construct, divided by 
its weight at the time of implantation, yielded its relative weight. A gain in weight is 
indicative for the disintegration of the network, which is accompanied by an uptake of 
water as shown in Fig. 3c. From a certain degree of disintegration on, the loss of PEG 
molecules of which all bonds had been hydrolyzed from the PEG hydrogel exceeds 
the water uptake and a net weight loss is observed9. As shown in Figs. 3 and 9, the 
implanted constructs first swell, and after 5 months start to lose weight. In vitro the 
degradation process proceeds faster. These constructs were completely solubilized 
after 5 months, whereas the implants still had about 150% of their original weight. 
The difference may reflect the more efficient removal of hydrolyzed PEG molecules 
from the constructs in vitro, since in vivo a capsule forms around the implant. As 
shown in Fig. 4, the capsule thickens substantially between 3 and 6 months, most 
likely as result of an increase in osmotic pressure induced by the degradation of the 
gel. The stabilization of the PEG hydrogel by the surrounding fibrous capsule restricts 
the maximal swelling compared to in vitro results by 20% (Fig. 9). Therefore, the 
capsule reduces the overall water-uptake of the PEG shell, in particular between 3 and 
6 months, and slows the disintegration of the material down. At 7 months, the PEG 
shell has completely degraded, since the overall mass had decreased to less than a 
third of that of the original implant without capsule. Thus, the capsule around the 
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hydrogel material does not block the transport of the soluble degradation products of 
the PEG hydrogel, i.e. PEG molecules of which all bonds to the remaining gel had 
been hydrolyzed, away from the implant site, but might act as a molecular sieve that 
allows only the transport of degradation products of relatively low molecular weight 
in the range of one or a few PEG molecules of ca. 2 kDa each.  
 
4. Conclusion 
A newly developed PEG-based hydrogel was shown to reduce cell in-growth for at 
least 1 month and tissue in-growth for more than 4 months in a subcutaneous in-
growth model. The material fulfills the criteria for a biodegradable adhesion barrier 
for use in abdominal surgery and as a guided bone regeneration membrane in dental 
implantology, since it exerts its barrier functions up to 4 months and is completely 
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Fig. 1. Subcutaneous implant model.  a) Placement of the gels into the subcutaneous 
pockets of the dorsal skin ,  b) implant scheme: The fibrin-soaked PVA sponge is 
covered by a three-dimensional PEG-hydrogel shell and implanted as test construct. 
PVA sponges without membrane coverage were transplanted as positive controls.  
 
Fig. 2. Formation of the PEG-hydrogel with CMC (closed circles) and without CMC 
(open circles) at 37°C, ω = 10 s-1 and γ = 2%. The gel point is characterized by the 
crossing of the G’ and G” curves at approximately 30 s after mixing the components. 
Both materials behave predominantly elastic after gelation. 
 
Fig. 3. Explants at different time points.  a) Positive control 1.0 month after 
implantation. The sponge is well infiltrated with newly formed tissue; Membrane 
samples  b) 1.0 month,  c) 4.3 months, and  d) 7.0 months post-implantation. 1 month 
after implantation the cellular capsule is thin, the edges of the PEG shell are clearly 
visible. After more than 4 months noticeable disintegration of the implants has taken 
place and water uptake into PEG network and capsule occurs. At 7 months post-
surgery the sample has shrunk to the size of the remaining sponge reflecting the 
almost complete breakdown of the hydrogel material. Scale bars: 3 mm. 
 
Fig. 4. Overview of explants at two different time points. Sections are stained with 
H&E.  a) 3.1 months and  b) 6.0 months after implantation. 3 months post-
implantation the cell containing capsule is a thin blue layer around the membrane 
(arrow heads). The PEG-hydrogel (pink) and the fibrin-filled sponge (dashed black 
line) are cell-free. After 6 months of implantation the fibrous capsule is thickened and 
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cell clusters have invaded both, hydrogel and sponge (dotted red lines in pink 
hydrogel). Dark blue lines are staining artifacts. 
 
Fig. 5. Capsule formation around PEG hydrogels at two different time points. 
Sections are stained with H&E (a+c) or an immunohisto chemistry staining for 
macrophages was performed.  
1 month after implantation:  a)  H&E, b)  macrophage stain  
3 months after implantation:  c)  H&E, d)  macrophage stain 
 
Fig. 6. Overview of the fibrin-filled sponges of explants at two different time points. 
Sections are stained with DAPI. 
Explants after three months: a) positive control and b) sponge cover with PEG 
hydrogel 
Explants after 7 months: c) positive control and d) sponge cover with PEG hydrogel.  
 
Three months after implantation no cellular infiltrate is detectable in membrane 
samples. Whereas after 7 months an increasing number of cells could be vizualized in 
these samples. 
 
Fig. 7. Cell infiltration into the positive controls. The dotted black line indicates the 
average value for all positive samples; the dotted gray lines the standard deviation. 
This graph shows the immediate cellular infiltration of the fibrin-filled sponges after 
implantation: at 1 month post-implantation the cell density has almost reached the 
overall average value of all positive controls. Thus, the fibrin-soaked PVA sponges 
provide a very powerful positive control. 
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 Fig. 8. Cell infiltration as a percentage of the average cell infiltration into the positive 
controls. Individual points are indicated with open circles, average values (±SD) with 
crosses. The blue line indicates an exponential curve fit. Until 4.6 months post-
implantation cellular infiltration is well below 1% of that of the positive control and 
the membrane can be regarded as tissue occlusive. After 6 months and more the 
infiltration rate increases exponentially, although the average infiltration after 7 
months is still lower than 3% of the positive control. 
 
Fig. 9. Comparison of in vivo and in vitro degradation of the membrane samples. 
Explanted gels were weighed without capsule for the first two months; from 3 months 
on, most of the gels had to be weighed with capsule in order to preserve their 
integrity, thus somewhat exaggerating the weight of the explants. The degradation 
process occurred faster in vitro than in vivo due to reduced swelling of the 
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